In office barely two months, the Biden administration is winning high praise from leaders of the medtech trade group AdvaMed.
That applies to the new administration’s use of the Defense Production Act for COVID supplies to its deliberation in choosing someone to lead the FDA. It doesn’t hurt that the $1.9 trillion pandemic relief bill that President Biden signed into law today includes $500 million in general-purpose funding for the FDA. How much of that might be directed to the Center for Devices and Radiological Health, which regulates medical devices, remains to be seen.
“The most important thing now is to make sure that the money is spent wisely,” AdvaMed president & CEO Scott Whitaker told reporters at a news conference yesterday.
Whitaker added in a statement after Biden’s prime time address to the country last night: “We look forward to continuing our collaboration with the administration to help save lives, get the economy back on track and return to normal for everyone.”
This story originally ran on Thursday, March 11, 2021. Updated on March 12 with Whitaker’s statement after Biden’s evening address.